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Phosphatase inhibitionBoth radiotherapy and most effective chemotherapeutic agents induce different types of DNA dam-
age. Here we show that tungstate modulates cell response to DNA damaging agents. Cells treated
with tungstate were more sensitive to etoposide, phleomycin and ionizing radiation (IR), all of
which induce DNA double-strand breaks (DSBs). Tungstate also modulated the activation of the cen-
tral DSB signalling kinase, ATM, in response to these agents. These effects required the functionality
of the Mre11–Nbs1–Rad50 (MRN) complex and were mimicked by the inhibition of PP2A phospha-
tase. Therefore, tungstate may have adjuvant activity when combined with DNA-damaging agents in
the treatment of several malignancies.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Despite great advances in our understanding of the biology of
cancer and new approaches using gene or targeted therapy, cancer
treatment still primarily consists of surgery when possible, fol-
lowed by chemo- and radio-therapy. The development of new anti-
cancer drugs is an inefﬁcient and costly process that takes around
10–15 years and an investment of over $1 billion USD for an aver-
age new molecule to enter the market. In addition, data suggests
that the overall success rate for oncology products in clinical devel-
opment is 10% [1,2].
The ultimate goal of chemo- and radio-therapy is to selectively
kill cancer cells while sparing healthy ones and minimizing side ef-
fects. The most effective chemotherapeutic agents and radio-
therapy strategies induce DNA damage. DNA double-strand breaks
(DSBs), one of the most cytotoxic types of DNA damage, trigger
signalling pathways that lead to cell death or senescence when
repair fails. The cellular response to DSBs is governed by the
Mre11–Rad50–Nbs1 (MRN) complex (Mre11–Rad50–Xrs2, MRX,
in budding yeast) which is a sensor of DSBs, and the Ataxia-telan-
giectasia mutated (ATM) kinase, a key transducer of the signallingresponse [3]. While DSB-based therapies effectively kill many can-
cer cells, they are also toxic to healthy dividing cell populations
like those in the bone marrow and gastrointestinal tract. Advances
in chemotherapy will depend on ﬁnding the key differences be-
tween tumoral and normal cells and taking advantage of them to
selectively kill certain cells.
One approach to this end is the identiﬁcation of adjuvants that
can increase the effectiveness of current therapies [4–7]. Ideally, an
adjuvant should be non-toxic, easy to administer and have known
pharmacological properties.
Tungstate can mimic, with a small toxicity proﬁle, most of the
effects of insulin, both in long- and short-term treatments [8,9]. So-
dium tungstate administered orally, normalizes glycemia, without
causing hypoglycemia, in many animal models of type 1 and 2 dia-
betes [9–12]. It can also signiﬁcantly reduce weight gain and adi-
posity by increasing energy dissipation and fatty acid oxidation
rates in obese rats [13]. The molecular mechanisms of tungstate ac-
tion remain poorly understood, but available data suggests that
they involve the inhibition of phosphatases [14–17]. This notion
has been linked to the capacity of this molecule to regulate trans-
lational control pathways [18]. While recent data in human pa-
tients showed no signiﬁcant anti-obesity activity of tungstate in
phase II clinical trials in the conditions and doses assayed [19] its
low toxicity proﬁle and potential to act on diverse physiological
processes make it a potential adjuvant in therapeutic protocols.
Here we report that micromolar concentrations of tungstate can
increase the toxicity of DSB inducing agents in both yeast and
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that these agents elicit. The molecular mechanism underlying this
effect involves the MRN complex and ATM pathway and is modu-
lated by the PP2A phosphatase. These results indicate that tung-
state should be considered a potential adjuvant for radio- and
chemo-therapy.
2. Materials and methods
2.1. Yeast growth assays
Yeast strains are described in Table 1. Standard methods for
yeast culture and manipulations were used [20].
For proliferation assays, exponentially growing cultures in li-
quid YPD were 20-fold diluted in the speciﬁed conditions. Growth
at 28.5 C was monitored in a Bioscreen C analyzer (Thermo Lab-
systems) as Abs420–580 measured every 30 min for 48 h. Data repre-
sented are the means of triplicates of each mutant and condition
versus untreated control.
2.2. Cell lines culture
Human HeLa cell line and wild type andMre11ATLD1/ATLD1 mouse
embryonic ﬁbroblasts (MEFs) were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM, Lonza) with 4.5 g/L glucose and supple-
mented with 10% Fetal Bovine Serum (FBS) and 1 mM glutamine.
Wild type and Mre11ATLD1/ATLD1 MEFs have been previously de-
scribed [21].
2.3. MTT viability assays
We followed the procedure published in [22]. Brieﬂy, the day
before treatment, the medium from cells in the logarithmic phase
was removed and replaced by 0.5% FBS DMEM. In the case of eto-
poside and phleomycin (Sigma) cells were treated for 3 h, after
which the medium was removed and substituted by fresh medium
without drug. For ionizing radiation (IR), the treatment lasted the
time required to reach the indicated doses. Tungstate at the indi-
cated concentrations was always present in the medium from 1 h
prior to challenge with DNA-damaging agents. The day after treat-
ment, the medium was removed and cells were incubated with
1 mg/ml MTT (Sigma) in culture medium for 2–3 h. Dye was then
extracted from the intact, viable cells with a solution of 0.1 N HCl
and 10% Triton (v/v) in isopropanol. The absorbance of solubilized
dye was then determined using a spectrophotometer equipped
with a 570 nm ﬁlter. Quantiﬁcation of the extracted MTT by spec-
trophotometry was normalized to mock-treated cultures. Statisti-
cal analysis was performed using a two-tailed t-test.
2.4. Immunoblotting
Cells seeded on p60 plates were scraped with 100 ll/plate of
25 mM HEPES, pH 7.3, 300 mM NaCl, 1.5 mMMgCl2, 0,1% (v/v) Tri-
ton X-100, 10 mM NaF, 1 mM sodium ortovanadate, 17.5 mM b-
glycerophosphate, 0.2 mM EDTA, 0.5 mM dithiothreitol, 20 nM
okadaic acid, 50 nM phenylmethylsulfonyl ﬂuoride, 10 lg/ml
aprotinine, 10 lg/ml leupeptine and 10 lg/ml pepstatine. 20 lgTable 1 Yeast strains.
Name Genotype Reference
W303.1a MATa leu2–3,112 his3–11,15 ura3–1 ade2–1 trp1–1
can1–100
[48]
Dmre11 W303.1a mre11::HIS3 [49]
Drad50 W303.1a rad50::TRP1 [49]
Dxrs2 W303.1a xrs2::LEU2 [49]
Dmrx W303.1a mre11::HIS3 rad50::TRP1 xrs2::LEU2 [49]of soluble protein extract was subjected to SDS–polyacrylamide
gel electrophoresis and transferred to PVDF (Immobilon-P;
Millipore) ﬁlters. Uniform gel loading was conﬁrmed by Ponceau
S staining of membranes after transfer. Phosphorylated ATM
(S1981) and Smc1 (S957) were detected with antiphosphoprotein
antibodies from Rockland. Antibodies against total ATM (Rockland)
and Mre11 (Abcam) proteins were used to ensure the even loading
of gels. Immunocomplexes were visualized by enhanced chemilu-
minescence detection (GE Life Sciences) using a HRP-conjugated
secondary antibody. The ﬁgures show an experiment representa-
tive of at least two independent ones with essentially identical
results.
2.5. Lentivirus production and shRNA gene silencing
Human MRE11A, NBN/NBS1 and RAD50 genes were silenced in
HeLa cells using the shRNA-based MISSION technology (Sigma)
with lentiviral particles. TRCN0000039872 (MRE11A),
TRCN0000040135 (NBN) or TRCN0000040104 (RAD50) shRNAs
were selected. Cells were incubated at 33 C and medium was col-
lected for 2 days. HeLa cells were infected with the produced len-
tiviruses and selected with 5 lg/mlpuromycin. As a control, an
shRNA designed to silence mouse Glycogen Synthase
(TRCN0000075796, noted as A8) with no effect on human cells,
was used.
2.6. Colony formation assay
The sensitivity of cells to IR was determined by colony forma-
tion assay as described [23]. Brieﬂy, logarithmic phase HeLa and
MEF cultures were irradiated at the indicated gray (Gy) doses
and reseeded for colony formation in triplicate. At 7–10 days after
plating, colonies were visualized by crystal violet staining and
counted. Colony numbers on plates receiving treatment were nor-
malized to mock-treated cultures. Statistical analysis was per-
formed using a two-tailed t-test.
2.7. Expression of recombinant proteins in HEK293T
HEK293T cells were seeded in p150 plates. When conﬂuent,
cells were transfected with 50 lg/plate of two pCDNA3-ﬂag con-
structs: PP2A and PP5. The ﬁrst day post-transfection the medium
was replaced by fresh DMEM (Lonza) cell culture medium supple-
mented with 10% FBS. On the second day post-transfection, cell
culture medium was removed, and 500 ll of cold lysis buffer
(30 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40,
1 mM benzamidine, 1 mM phenylmethylsulfonyl ﬂuoride, 25 nM
okadaic acid, 10 lg/ml leupeptin, 10 lg/ml aprotinin, and 10 lg/
ml pepstatin) was added per dish. Cells were collected using cell
scrapers and incubated in lysis buffer for 20 min in an orbital sha-
ker at 4 C and low speed. The extract was then centrifuged for
10 min at 5000g. The supernatant was then collected. Next,
200 ll of anti-Flag agarose resin (Sigma) was added to the extract,
and it was incubated overnight at 4 C using an overhead tumbler.
The following day cell extract with resin was centrifuged at
1000g and 4 C for 5 min. The resin was transferred to an Eppen-
dorf tube, where it was washed once using 500 ll of cold wash buf-
fer (30 mM Tris–HCl, pH 7.4, 150 mM NaCl and 0.1% Nonidet P-40)
and ﬁve times more with TBS. The resin was then incubated for
10 min with elution buffer (30 mM Tris–HCl, pH 7.4, 150 mM NaCl
and 500 lg/ml ﬂag peptide), and protein was eluted.
2.8. Protein phosphatase assays
Protein phosphatase activity using p-nitrophenylphosphate
(pNPP) as substrate was determined essentially as described [24].
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Fig. 1. Tungstate rescues proliferation of yeast MRX complex mutants upon DNA damage. Growth of W303.1a wild-type strain, Dmre11, Drad50 and Dxrs2 single mutants,
and a MRX complex triple mutant with (open symbols) or without (black symbols) 5 lg/mL phleomycin in the presence or absence of 1 mM tungstate. Raw Abs420–580 as
means of the triplicates are represented.
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2 mM MnCl2, and 0.2% (v/v) b-mercaptoethanol. Samples were
incubated for 10 min at 37 C, and then the reaction was stopped
by adding 1% Tris (ﬁnal concentration). For phosphatase inhibition
assays, a range of concentrations of tungstate were incubated with
the puriﬁed phosphatases for 10 min at 37 C, prior to the addition
of pNPP.3. Results
3.1. Tungstate rescues proliferation of yeast MRX complex mutants
upon DNA damage
Phleomycin is a glycopeptide antibiotic that belongs to the ble-
omycin family and causes DSBs in DNA. A Saccharomyces cerevisiae
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Fig. 2. Tungstate enhances the toxicity of DNA damaging agents in HeLa cells. MTT viability assays of HeLa cells: (A) incubated with increasing concentrations of phleomycin
or etoposide ±1 lM tungstate. (B) Irradiated with 10 or 20 Gy in the presence or absence of lM concentrations of tungstate. ⁄P < 0.05.
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mutants, along with the MRX complex triple mutant were sub-
jected to treatment with 5 lg/ml phleomycin. We tested the effect
of 1 mM tungstate on cell growth after phleomycin-induced DNA
damage. As expected, all MRX mutants showed a higher sensitivity
to phleomycin than the WT, specially the mrx triple mutant. Sur-
prisingly, tungstate alleviated sensitivity to phleomycin in all mu-
tant strains and had a dramatic effect on the triple mrx mutant
(Fig. 1). However, despite the strong effect on cell growth, viability
was not rescued (Suppl. Fig. 1). This result indicates that signalling
downstream of the MRX complex is impaired by tungstate after a
DNA damage challenge.
3.2. Tungstate enhances toxicity of DSB-inducing agents
Etoposide, phleomycin and IR all induce DNA damage, including
DSBs [25–27]. The MTT assay was used to assess the decrease in
HeLa cells viability caused by DSB-inducing agents in the presence
of several concentrations of tungstate. Tungstate was added 1 h
prior to the induction of DNA damage and maintained during
and following treatment. For each drug, tungstate treatment aug-
mented the toxicity of the DNA damaging agent in a dose depen-
dent manner (Fig. 2).
3.3. Tungstate modulates the kinetics of ATM pathway activation
ATM phosphorylation and subsequent activation of its kinase
activity is a hallmark of the DSB response [28] and Smc1 is a spe-
ciﬁc target of ATM phosphorylation [29]. HeLa cells were preincu-
bated or not with 1 lM tungstate for 1 h and then challenged with
1 or 10 lg/ml etoposide. Samples were collected at several time
points and immunodetection of active ATM was carried out using
an antibody for the S1981 autophosphorylation site. Tungstate
treatment enhanced the activation kinetics of ATM (Fig. 3A). A sim-
ilar effect was obtained when HeLa cells (Fig. 3B) and MEFs(Fig. 3C) were pre-incubated or not with 1 or 10 lM tungstate
for 1 h and then irradiated with 5 or 10 Gy. Samples were collected
before and 3 and 6 h after irradiation. Again, more robust phos-
phorylation of ATM was observed in the presence of tungstate.
3.4. Depletion of the MRN complex blocks tungstate-induced
enhancement of DNA damage
The Mre11–Nbs1–Rad50 (MRN) complex is a major component
of the ATM pathway. MRN is a sensor of DSBs and is required to
activate ATM and mediate its activation of targets including all
the members of the MRN complex and SMC1 [30]. MRN complex
constituents were individually depleted in HeLa cells by using
shRNA lentiviral expression. We achieved around a 75% reduction
in mRNA levels in every case, as measured by RT-qPCR (Suppl.
Fig. 2). When each of the MRN components was silenced, thus
compromising the function of the MRN complex, tungstate was un-
able to enhance etoposide-induced cell death (Fig. 4A). To conﬁrm
this observation, a colony formation assay was performed in HeLa
cells and MEFs irradiated in the presence or absence of tungstate.
Neither Mre11 shRNA-expressing HeLa cells (Fig. 4B), nor defective
mutant Mre11ATLD1/ATLD1 MEFs (Fig. 4C) were sensitive to the DNA-
damage-enhancing activity of tungstate. Of note, Mre11 shRNA-
expressing HeLa cells without tungstate treatment and WT cells
with it showed similar sensitivity to etoposide. This effect is con-
sistent with an impairment of Mre11 function.
3.5. Tungstate inhibits the ATM phosphatase PP2A in vitro
Tungstate inhibits several types of phosphatases [14–17], there-
fore it is reasonable to hypothesize that the inhibition of a protein
phosphatase explains the effect of this compound on the modula-
tion of ATM signalling. Protein phosphatase 2A (PP2A) and protein
phosphatase 5 (PP5) are two of the main phosphatases involved in
ATM dephosphorylation [31,32]. We used human PP2A and rat PP5
p-ATM
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Fig. 3. Tungstate modulates ATM and Smc1 phosporylation kinetics upon DNA damage. (A) Immunodetection of phospho-ATM (p-ATM) in HeLa cells treated with 1 or 10 lg/
mL etoposide for the hours indicated ±1 lM tungstate. (B) Immunodetection of p-ATM and phospho-Smc1 (p-Smc1) in HeLa cells irradiated with 5 or 10 Gy and with
indicated concentrations of tungstate for 3 h. (C) Immunodetection of p-ATM and phospho-Smc1 (p-Smc1) in wild-type MEFs irradiated with 5 or 10 Gy and with indicated
concentrations of tungstate for 3 h. Even loading of the gels was conﬁrmed by immunodetection of Mre11 protein.
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these phosphatases to tungstate. Tungstate inhibited PP2A
(Fig. 5A) with an IC50 nearly 10-fold lower than that described
for PP1 [18] and similar to the dose used on HeLa and MEFs. In con-
trast, tungstate was a poor inhibitor of PP5 (Fig. 5B).
3.6. In vivo inhibition of PP2A mimics the effects of tungstate on DNA
damage signalling
We addressed whether the inhibition of PP2A phosphatase is in-
volved in the role of tungstate on the modulation of the DNA-dam-
age response (DDR) modulation. For this purpose, we treated HeLa
cells with etoposide in the presence or absence of okadaic acid
(OA), a potent inhibitor of PP2A, and to a lesser extent PP1 [33].
OAmimicked the cell responses to etoposide-induced DNA damage
caused by tungstate (Fig. 6) as it increased cell death and modu-
lated ATM phosphorylation.
4. Discussion
Our study shows that tungstate interferes with DDR signalling
triggered by the MRN complex in yeast and mammals. Consistent
with this, tungstate enhanced the toxicity of DSB-inducing agents
in HeLa cells and MEFs. Tungstate modulated the kinetics of ATM
activation. This effect appears to require a functional MRN com-
plex, as depletion of any of its components blocked the effect. To
our knowledge this is the ﬁrst study to report that tungstate partic-ipates in the MRN-ATM response to DNA damage. Our results sug-
gest the involvement of a negative regulator of the ATM pathway,
which would be blocked by tungstate. Indeed, tungstate inhibited
the ATM phosphatase PP2A in vitro. Accordingly, the PP2A inhibi-
tor OA mimicked the tungstate-induced phenotype.
In budding yeast, tungstate alleviated the growth defect in MRX
complex single mutants and, more dramatically, in the MRX triple
mutant upon phleomycin-induced DNA damage. As these mutants
are fully defective in DSB repair machinery but only partially defec-
tive in checkpoint signalling, this effect indicates that tungstate af-
fects signalling downstream of MRX.
Accordingly, tungstate treatment enhanced the toxicity of a
variety of agents that generate DSBs, such as phleomycin, etopo-
side and IR in a human cell line. Analysis of ATM activation and
substrates such as SMC1 showed that the ATM signalling cascade
was activated in these treatments and was affected by tungstate
[3]. The MRN complex has diverse functions in DNA damage recog-
nition [34], cell cycle checkpoint activation [35], non-homologous
end joining [36] and telomere maintenance [37]. The MRN com-
plex binds DSB soon after they are formed implicating it in DNA
damage detection [38], thus acting upstream ATM and allowing
its activation. The complex can tether linear duplex molecules
[39], and it is able to bridge broken DNA ends or sister chromatids
[40]. MRN function is complex as it also acts downstream of ATM
to facilitate the phosphorylation of numerous substrates including
Smc1 and Chk2 [3]. On the basis of our results, we hypothesize that
action of tungstate on the ATM kinase is exerted upstream, at the
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Fig. 4. Downregulation of the MRN complex abolishes the effect of tungstate on DNA damage response. (A) MTT viability assay of HeLa cells stably expressing shRNA for MRN
complex constituents, treated with increasing concentrations of etoposide ±1 lM tungstate. (B) Colony formation assay of HeLa cells stably expressing control and Mre11
shRNA and irradiated with 5 or 10 Gy in the presence of increasing concentrations of tungstate. (C) Colony formation assay of wild type and Mre11ATLD1/ATLD1 cells irradiated
with 5 or 10 Gy in the presence of increasing concentrations of tungstate. ⁄P < 0.05.
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ulation of the kinase.
The intensiﬁcation of the DDR by tungstate requires the MRN
complex. Although inherited mutations in MRE11A and NBN/NBS1
genes are responsible for the cancer-prone syndromes ataxia telan-
giectasia-like disorder (ATLD) and Nijmegen breakage syndrome
(NBS), these essential genes are neither extensively mutated nor
is their expression in tumors greatly reduced, as breast cancer data
show [41,42]. Moreover, an intact MRN complex has been corre-
lated with effective eradication of tumor cells by radio-therapy[43]. Tungstate action could take advantage of the frequent conser-
vation of MRN function in tumors in order to improve the DDR and
increase the cytotoxicity elicited by DNA damaging agents.
The inhibition of the PP2A phosphatase by tungstate seems to
mediate ATM overactivation, as this effect was mimicked by OA
treatment. Apart from ATM dephosphorylation [32], PP2A is impli-
cated in the regulation of numerous signalling pathways and it
may function as a tumor suppressor. Pharmacological modulation
of PP2A activity has recently shown promising therapeutic activity
for the treatment of cancer [44].
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of Mre11 nuclease activity by tungstate. Mre11 contains sequence
motifs equivalent to those of the PP1 catalytic site, recently de-
scribed to be inhibited by tungstate [18], and they are importantfor the nuclease activity of the protein [45]. Although the contribu-
tion of this activity to DSB processing is controversial, the phospha-
tase inhibitory activity of tungstate could impair Mre11 nuclease
activity during DDR and thus enhance cytotoxicity.
Apart from their pivotal role in responding and repairing extrin-
sically induced DNA damage, ATM and the MRN complex also par-
ticipate in DNA-replication stress [46]. This event guarantees the
ﬁdelity of DNA replication as it can stop when DNA damage is de-
tected. It is estimated that DNA damage occurs at a rate of 1000 to
1000000 molecular lesions per cell per day [47]. Whether tung-
state affects this everyday process in a relevant manner deserves
further investigation.
Tungstate shows anti-diabetic and anti-obesity effects in many
experimental models. Unfortunately data obtained from phase II
clinical trials do not support tungstate as a pharmacological agent
for the treatment of obesity [19]. Nevertheless it has passed phase I
trials, so data are available regarding its safety, tolerability and
pharmacokinetics. Furthermore, the pathways potentially regu-
lated by this compound, according to the literature, are multiple.
For all these reasons, it is extremely attractive to explore new ther-
apeutic potentials of tungstate.
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